{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:15:12Z","timestamp":1793132112558,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00198-021-05997-1","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T07:02:54Z","timestamp":1621407774000},"page":"1937-1949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia. A comprehensive review"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0872-6765","authenticated-orcid":false,"given":"S.","family":"Giannini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rendina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Massoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lazzerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"5997_CR1","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1210\/jc.2011-1319","volume":"97","author":"EA Imel","year":"2012","unstructured":"Imel EA, Econs MJ (2012) Approach to the hypophosphatemic patient. J Clin Endocrinol Metab 97:696\u2013706. https:\/\/doi.org\/10.1210\/jc.2011-1319","journal-title":"J Clin Endocrinol Metab"},{"key":"5997_CR2","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1007\/s00467-012-2175-z","volume":"27","author":"MG Penido","year":"2012","unstructured":"Penido MG, Alon US (2012) Phosphate homeostasis and its role in bone health. Pediatr Nephrol 27:2039\u20132048. https:\/\/doi.org\/10.1007\/s00467-012-2175-z","journal-title":"Pediatr Nephrol"},{"key":"5997_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1177\/0004563214521399","volume":"51","author":"P Manghat","year":"2014","unstructured":"Manghat P, Sodi R, Swaminathan E (2014) Phosphate homeostasis and disorders. Ann Clin Biochem 51:631\u2013656. https:\/\/doi.org\/10.1177\/0004563214521399","journal-title":"Ann Clin Biochem"},{"key":"5997_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.beem.2018.06.004","volume":"32","author":"M Christov","year":"2018","unstructured":"Christov M, Juppner H (2018) Phosphate homeostasis disorders. Best Pract Res Clin Endocrinol Metab 32:685\u2013706. https:\/\/doi.org\/10.1016\/j.beem.2018.06.004","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"5997_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fendo.2019.00180","volume":"10","author":"T Michigami","year":"2019","unstructured":"Michigami T, Ozono K (2019) Roles of phosphate in skeleton. Front Endocrinol 10:180. https:\/\/doi.org\/10.3389\/fendo.2019.00180","journal-title":"Front Endocrinol"},{"key":"5997_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.proeng.2015.07.003","volume":"110","author":"JMDA Rollo","year":"2015","unstructured":"Rollo JMDA, Boffa RS, Cesar R, Schwab DC, Leivas TP (2015) Assessment of trabecular bones microarchitectures and crystal structure of hydroxyapatite in bone osteoporosis with application of the Rietveld method. Procedia Engineering 110:8\u201314. https:\/\/doi.org\/10.1016\/j.proeng.2015.07.003","journal-title":"Procedia Engineering"},{"key":"5997_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1172\/JCI19081","volume":"113","author":"T Shimada","year":"2004","unstructured":"Shimada T, Kakitani M, Yamamzaki Y, Hasegawa H, Takeuchi Y, Fujita T et al (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561\u2013568. https:\/\/doi.org\/10.1172\/JCI19081","journal-title":"J Clin Invest"},{"key":"5997_CR8","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/ki.2014.316","volume":"86","author":"B Lanske","year":"2014","unstructured":"Lanske B, Razzaque MS (2014) Molecular interactions of FGF23 and PTH in phosphate regulation. Kidney Int 86:1072\u20131074. https:\/\/doi.org\/10.1038\/ki.2014.316","journal-title":"Kidney Int"},{"key":"5997_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11154-011-9199-8","volume":"13","author":"MR Haussler","year":"2012","unstructured":"Haussler MR, Whitfield GK, Kaneko I, Forster R, Saini R, Hsieh J et al (2012) The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis. Rev Endocr Metab Disord 13:57\u201369. https:\/\/doi.org\/10.1007\/s11154-011-9199-8","journal-title":"Rev Endocr Metab Disord"},{"key":"5997_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ncpneph0124","volume":"2","author":"J Amanzadeh","year":"2006","unstructured":"Amanzadeh J, Reilly RF (2006) Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol 2:136\u2013148. https:\/\/doi.org\/10.1038\/ncpneph0124","journal-title":"Nat Clin Pract Nephrol"},{"key":"5997_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ng1095-130","volume":"11","author":"F Francis","year":"1995","unstructured":"Francis F, Hennig S, Korn B, Reinhardt R, De Jong P, Poustka A et al (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130\u2013136. https:\/\/doi.org\/10.1038\/ng1095-130","journal-title":"Nat Genet"},{"key":"5997_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.bone.2013.01.046","volume":"54","author":"JQ Feng","year":"2013","unstructured":"Feng JQ, Clinkenbeard EL, Yuan B, White KE, Drezner MK (2013) Osteocyte regulation of phosphate homeostasis and bone mineralization underlies the pathophysiology of the heritable disorders of rickets and osteomalacia. Bone 54:213\u2013221. https:\/\/doi.org\/10.1016\/j.bone.2013.01.046","journal-title":"Bone"},{"key":"5997_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","volume":"14","author":"SS Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G, de Lucas Collantes C, Schnabel D, Jandhyala R, M\u00e4kitie O (2019) FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis 14:58. https:\/\/doi.org\/10.1186\/s13023-019-1014-8","journal-title":"Orphanet J Rare Dis"},{"key":"5997_CR14","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMra0904186","volume":"362","author":"D Pri\u00e9","year":"2010","unstructured":"Pri\u00e9 D, Friedlander G (2010) Genetic disorders of renal phosphate transport. N Engl J Med 362:2399\u20132409. https:\/\/doi.org\/10.1056\/NEJMra0904186","journal-title":"N Engl J Med"},{"key":"5997_CR15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/0022034516677528","volume":"96","author":"M Biosse Duplan","year":"2017","unstructured":"Biosse Duplan M, Coyac BR, Bardet C, Zadikian C, Rothenbuhler A, Kamenicky P, Briot K, Linglart A, Chaussain C (2017) Phosphate and vitamin D prevent periodontitis in X- linked hypophosphatemia. J Dent Res 96:388\u2013395. https:\/\/doi.org\/10.1177\/0022034516677528","journal-title":"J Dent Res"},{"key":"5997_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s10354-019-00732-2","volume":"170","author":"A Raimann","year":"2020","unstructured":"Raimann A, Mindler GT, Kocijan R, Bekes K, Zwerina J, Haeusler G, Ganger R (2020) Multidisciplinary patient care in X-linked hypophosphatemic rickets: one challenge, many perspectives. Wien Med Wochenschr 170:116\u2013123. https:\/\/doi.org\/10.1007\/s10354-019-00732-2","journal-title":"Wien Med Wochenschr"},{"key":"5997_CR17","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, Kamenicky P, Nevoux J, Pri\u00e9 D, Rothenbuhler A, Wicart P, Harvengt P (2014) Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect 3:R13\u2013R30. https:\/\/doi.org\/10.1530\/EC-13-0103","journal-title":"Endocr Connect"},{"key":"5997_CR18","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1210\/JC.2015-2199","volume":"100","author":"J Connor","year":"2015","unstructured":"Connor J, Olear EA, Insogna KL, Katz L, Baker S, Kaur R, Simpson CA, Sterpka J, Dubrow R, Zhang JH, Carpenter TO (2015) Conventional therapy in adults with X-Linked hypophosphatemia: effects on enthesopathy and dental disease. J Clin Endocrinol Metab 100:3625\u20133632. https:\/\/doi.org\/10.1210\/JC.2015-2199","journal-title":"J Clin Endocrinol Metab"},{"key":"5997_CR19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-08-0818","volume":"160","author":"SS Beck-Nielsen","year":"2009","unstructured":"Beck-Nielsen SS, Brock-Jacobsen B, Gram J, Brixen K, Jensen TK (2009) Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol 160:491\u2013497. https:\/\/doi.org\/10.1530\/EJE-08-0818","journal-title":"Eur J Endocrinol"},{"key":"5997_CR20","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","volume":"62","author":"I Endo","year":"2015","unstructured":"Endo I, Fukumoto S, Ozono K, Namba N, Inoue D, Okazaki R, Yamauchi M, Sugimoto T, Minagawa M, Michigami T, Nagai M, Matsumoto T (2015) Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 62:811\u2013816. https:\/\/doi.org\/10.1507\/endocrj.EJ15-0275","journal-title":"Endocr J"},{"key":"5997_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/EJE-15-0515","volume":"174","author":"S Rafaelsen","year":"2016","unstructured":"Rafaelsen S, Johansson S, R\u00e6der H, Bjerknes R (2016) Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur J Endocrinol 174:125\u2013136. https:\/\/doi.org\/10.1530\/EJE-15-0515","journal-title":"Eur J Endocrinol"},{"key":"5997_CR22","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"EA Imel","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL (2011) A clinicians\u2019 guide to x-linked hypophosphatemia. J Bone Miner Res 26:1381\u20131388. https:\/\/doi.org\/10.1002\/jbmr.340","journal-title":"J Bone Miner Res"},{"key":"5997_CR23","doi-asserted-by":"crossref","unstructured":"Hawley S, Shaw NJ, Delmestri A, Prieto-Alhambra D, Cooper C, Pinedo-Villanueva R, Javaid MK (2020) Prevalence and mortality of individuals with X-linked hypophosphataemia: a United Kingdom real world data analysis. J Clin Endocrinol Metab 105. pii: dgz203.","DOI":"10.1210\/clinem\/dgz203"},{"key":"5997_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11136-020-02465-x","volume":"29","author":"SH Lo","year":"2020","unstructured":"Lo SH, Lachmann R, Williams A, Piglowska N, Lloyd AJ (2020) Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study. Qual Life ResMar 29:11\u20131893. https:\/\/doi.org\/10.1007\/s11136-020-02465-x","journal-title":"Qual Life ResMar"},{"key":"5997_CR25","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s12325-019-01193-0","volume":"37","author":"N Ferizovic\u2019","year":"2020","unstructured":"Ferizovic\u2019 N, Marshall J, Williams AE, Mughal MZ, Shaw N, Mak C, Gardiner O, Hossain P, Upadhyaya (2020) Exploring the burden of X-Linked hypophosphataemia: an opportunistic qualitative study of patient statements generated during a technology appraisal. Adv Ther 37:770\u2013784. https:\/\/doi.org\/10.1007\/s12325-019-01193-0","journal-title":"Adv Ther"},{"key":"5997_CR26","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1210\/js.2018-00365","volume":"3","author":"A Skrinar","year":"2019","unstructured":"Skrinar A, Dvorak-Ewell M, Evins A, Macica C, Linglart A, Imel EA, Theodore-Oklota C, San Martin J (2019) The lifelong impact of x-linked hypophosphatemia: results from a burden of disease survey. J Endocrine Soc 3:1321\u20131334. https:\/\/doi.org\/10.1210\/js.2018-00365","journal-title":"J Endocrine Soc"},{"key":"5997_CR27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, Wicart P, Bockenhauer D, Santos F, Levtchenko E, Harvengt P, Kirchhoff M, di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenicky P, Rejnmark L, Linglart A (2019) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 15:435\u2013455. https:\/\/doi.org\/10.1038\/s41581-019-0152-5","journal-title":"Nat Rev Nephrol"},{"key":"5997_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00223-010-9373-0","volume":"87","author":"SS Beck-Nielsen","year":"2010","unstructured":"Beck-Nielsen SS, Brusgaard K, Rasmussen LM, Brixen K, Brock-Jacobsen B, Poulsen MR, Vestergaard P, Ralston SH, Albagha OME, Poulsen S, Haubek D, Gj\u00f8rup H, Hintze H, Andersen MG, Heickendorff L, Hjelmborg J, Gram J (2010) Phenotype presentation of hypophosphatemic rickets in adults. Calcif Tissue Int 87:108\u2013119. https:\/\/doi.org\/10.1007\/s00223-010-9373-0","journal-title":"Calcif Tissue Int"},{"key":"5997_CR29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/EJE-15-0661","volume":"174","author":"H Che","year":"2016","unstructured":"Che H, Roux C, Etcheto A, Rothenbuhler A, Kamenicky P, Linglart A, Briot K (2016) Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol 174:325\u2013333. https:\/\/doi.org\/10.1530\/EJE-15-0661","journal-title":"Eur J Endocrinol"},{"key":"5997_CR30","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","volume":"41","author":"D Chesher","year":"2018","unstructured":"Chesher D, Oddy M, Darbar U, Sayal P, Casey A, Ryan A, Sechi A, Simister C, Waters A, Wedatilake Y, Lachmann RH, Murphy E (2018) Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutation. J Inherit Metab Dis 41:865\u2013876. https:\/\/doi.org\/10.1007\/s10545-018-0147-6","journal-title":"J Inherit Metab Dis"},{"key":"5997_CR31","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1007\/s00198-018-4618-2","volume":"29","author":"G Marcucci","year":"2018","unstructured":"Marcucci G, Masi L, Ferrari S, Haffner D, Javaid MK, Kamenicky\u2019 P et al (2018) Phosphate wasting disorders in adults. Osteoporos Int 29:2369\u20132387. https:\/\/doi.org\/10.1007\/s00198-018-4618-2","journal-title":"Osteoporos Int"},{"key":"5997_CR32","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1210\/jcem.86.8.7761","volume":"86","author":"IA Holm","year":"2001","unstructured":"Holm IA, Nelson AE, Robinson BG, Mason RS, Marsh DJ, Cowell CT, Carpenter TO (2001) Mutational analysis and genotype-phenotype correlation of the PHEX gene in X- linked hypophosphatemic rickets. J Clin Endocrinol Metab 86:3889\u20133899. https:\/\/doi.org\/10.1210\/jcem.86.8.7761","journal-title":"J Clin Endocrinol Metab"},{"key":"5997_CR33","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.bone.2008.06.002","volume":"43","author":"S Ichikawa","year":"2008","unstructured":"Ichikawa S, Traxler EA, Estwick SA, Curry LR, Johnson ML, Sorenson AH, Imel EA, Econs MJ (2008) Mutational survey of the PHEX gene in patients with X- linked hypophosphatemic rickets. Bone 43:663\u2013666. https:\/\/doi.org\/10.1016\/j.bone.2008.06.002","journal-title":"Bone"},{"key":"5997_CR34","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1302\/1863-2548.11.170003","volume":"11","author":"A Horn","year":"2017","unstructured":"Horn A, Wright J, Bockenhauer D, Van\u2019t Hoff W, Eastwood DM (2017) The orthopaedic management of lower limb deformity in hypophosphataemic rickets. J Child Orthop 11:298\u2013305. https:\/\/doi.org\/10.1302\/1863-2548.11.170003","journal-title":"J Child Orthop"},{"key":"5997_CR35","unstructured":"Skrinar A, Marshall A, San Martin J, Dvorak-Ewell M. X-linked hypophosphatemia (XLH) impairs skeletal health outcomes and physical function in affected adults. Poster presented at the ENDO meeting held in San Diego (USA) on 5-8 March, 2015."},{"key":"5997_CR36","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1445-5994.1981.tb04223.x","volume":"11","author":"DW Cartwright","year":"1981","unstructured":"Cartwright DW, Masel JP, Latham SC (1981) The lumbar spinal canal in hypophosphataemic vitamin D-resistant rickets. Aust NZ J Med 11:154\u2013157. https:\/\/doi.org\/10.1111\/j.1445-5994.1981.tb04223.x","journal-title":"Aust NZ J Med"},{"key":"5997_CR37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1148\/radiology.171.2.2539609","volume":"171","author":"DC Hardy","year":"1989","unstructured":"Hardy DC, Murphy WA, Siegel BA, Reid IR, Whyte MP (1989) X-linked hypophosphatemia in adults: prevalence of skeletal radiographic and scintigraphic features. Radiology 171:403\u2013414. https:\/\/doi.org\/10.1148\/radiology.171.2.2539609","journal-title":"Radiology"},{"key":"5997_CR38","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/sca.21141","volume":"36","author":"I Cremonesi","year":"2014","unstructured":"Cremonesi I, Nucci C, D\u2019Alessandro G, Alkhamis N, Marchionni S, Piana G (2014) X-linked hypophosphatemic rickets: enamel abnormalities and oral clinical findings. Scanning 36:456\u2013461. https:\/\/doi.org\/10.1002\/sca.21141","journal-title":"Scanning"},{"issue":"1","key":"5997_CR39","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/cen.13346","volume":"87","author":"US Alon","year":"2017","unstructured":"Alon US, Jarka D, Monachino PJ, Sebestyen VanSickle J, Srivastava T (2017) Cinacalcet as an alternative to phosphate therapy in X-linked hypophosphataemic rickets. Clin Endocrinol 87(1):114\u2013116. https:\/\/doi.org\/10.1111\/cen.13346","journal-title":"Clin Endocrinol"},{"key":"5997_CR40","first-page":"370","volume":"19","author":"P Anagnostis","year":"2019","unstructured":"Anagnostis P, Vamvakidis K, Tournis S (2019) Successful management of tertiary hyperparathyroidism associated with hypophosphataemic rickets in an adult. J Musculoskelet Neuronal Interact 19:370\u2013373","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"5997_CR41","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/jbmr.1838","volume":"28","author":"T Srivastava","year":"2013","unstructured":"Srivastava T, Alon US (2013) Cinacalcet as adjunctive therapy for hereditary 1,25-dihydroxyvitamin D-resistant rickets. J Bone Miner Res 28:992\u2013996. https:\/\/doi.org\/10.1002\/jbmr.1838","journal-title":"J Bone Miner Res"},{"key":"5997_CR42","doi-asserted-by":"publisher","first-page":"274","DOI":"10.14310\/horm.2002.1277","volume":"9","author":"MP Yavropoulou","year":"2010","unstructured":"Yavropoulou MP, Kotsa K, Gotzamani Psarrakou A, Papazisi A, Tranga T, Ventis S, Yovos JG (2010) Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review. Hormones (Athens) 9:274\u2013278. https:\/\/doi.org\/10.14310\/horm.2002.1277","journal-title":"Hormones (Athens)"},{"issue":"Suppl 1","key":"5997_CR43","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1530\/EJE-08-0383","volume":"159","author":"H Raeder","year":"2008","unstructured":"Raeder H, Shaw N, Netelenbos C, Bjerknes R (2008) A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet. Eur J Endocrinol 159(Suppl 1):S101\u2013S105. https:\/\/doi.org\/10.1530\/EJE-08-0383","journal-title":"Eur J Endocrinol"},{"key":"5997_CR44","doi-asserted-by":"publisher","first-page":"658","DOI":"10.2215\/CJN.04981107","volume":"3","author":"US Alon","year":"2008","unstructured":"Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD (2008) Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol 3:658\u2013664. https:\/\/doi.org\/10.2215\/CJN.04981107","journal-title":"Clin J Am Soc Nephrol"},{"key":"5997_CR45","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4158\/EP.12.3.294","volume":"12","author":"CR McHenry","year":"2006","unstructured":"McHenry CR, Mostafavi K, Murphy TA (2006) Tertiary hyperparathyroidism attributable to long-term oral phosphate therapy. Endocr Pract 12:294\u2013298. https:\/\/doi.org\/10.4158\/EP.12.3.294","journal-title":"Endocr Pract"},{"issue":"3","key":"5997_CR46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1507\/endocrj.EJ16-0199","volume":"64","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Takagi M, Takeda R, Miyai K, Hasegawa Y (2017) Hypertension Is a Characteristic Complication of X-linked Hypophosphatemia. Endocr J 64(3):283\u2013289. https:\/\/doi.org\/10.1507\/endocrj.EJ16-0199","journal-title":"Endocr J"},{"key":"5997_CR47","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1210\/jcem.82.8.4181","volume":"82","author":"R Nehgme","year":"1997","unstructured":"Nehgme R, Fahey JT, Smith C, Carpenter TO (1997) Cardiovascular abnormalities in patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 82:2450\u20132454. https:\/\/doi.org\/10.1210\/jcem.82.8.4181","journal-title":"J Clin Endocrinol Metab"},{"key":"5997_CR48","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.amjoto.2015.10.002","volume":"37","author":"S Kaya","year":"2016","unstructured":"Kaya S, Tsuprun V, Hizli O, Schachern PA, Paparella MM, Cureoglu S (2016) Cochlear changes in serous labyrinthitis associated with silent otitis media: a human temporal bone study. Am J Otolaryngol 37:83\u201388. https:\/\/doi.org\/10.1016\/j.amjoto.2015.10.002","journal-title":"Am J Otolaryngol"},{"key":"5997_CR49","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/0022034517728497","volume":"97","author":"BR Coyac","year":"2018","unstructured":"Coyac BR, Hoac B, Chafey P, Falgayrac G, Slimani L, Rowe PS, Penel G, Linglart A, McKee MD, Chaussain C, Bardet C (2018) Defective mineralization in X-linked hypophosphatemia dental pulp cell cultures. J Dent Res 97:184\u2013191. https:\/\/doi.org\/10.1177\/0022034517728497","journal-title":"J Dent Res"},{"key":"5997_CR50","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00467-002-1044-6","volume":"18","author":"US Alon","year":"2003","unstructured":"Alon US, Monzavi R, Lilien M, Rasoulpour M, Geffner ME, Yadin O (2003) Hypertension in hypophosphatemic rickets--role of secondary hyperparathyroidism. Pediatr Nephrol 18:155\u2013158. https:\/\/doi.org\/10.1007\/s00467-002-1044-6","journal-title":"Pediatr Nephrol"},{"key":"5997_CR51","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00223-020-00695-2","volume":"108","author":"G Marcucci","year":"2021","unstructured":"Marcucci G, Brandi ML (2021) Congenital conditions of hypophosphatemia expressed in adults. Calcif Tissue Int 108:91\u2013103. https:\/\/doi.org\/10.1007\/s00223-020-00695-2","journal-title":"Calcif Tissue Int"},{"key":"5997_CR52","doi-asserted-by":"publisher","first-page":"154049","DOI":"10.1016\/j.metabol.2019.154049","volume":"103S","author":"AL Lecoq","year":"2020","unstructured":"Lecoq AL, Brandi ML, Linglart A, Kamenicky P (2020) Management of X-linked hypophosphatemia in adults. Metabolism 103S:154049. https:\/\/doi.org\/10.1016\/j.metabol.2019.154049","journal-title":"Metabolism"},{"key":"5997_CR53","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00223-012-9651-0","volume":"91","author":"JM Pettifor","year":"2012","unstructured":"Pettifor JM, Thandrayen K (2012) Hypophosphatemic rickets: unravelling the role of FGF23. Calcif Tissue Int 91:297\u2013306. https:\/\/doi.org\/10.1007\/s00223-012-9651-0","journal-title":"Calcif Tissue Int"},{"key":"5997_CR54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00223-020-00664-9","volume":"108","author":"E Koumakis","year":"2021","unstructured":"Koumakis E, Cormier C, Roux C, Briot K (2021) The causes of hypo- and hyperphosphatemia in humans. Calcif Tissue Int 108:41\u201373. https:\/\/doi.org\/10.1007\/s00223-020-00664-9","journal-title":"Calcif Tissue Int"},{"key":"5997_CR55","doi-asserted-by":"publisher","first-page":"5906","DOI":"10.1210\/en.2012-1551","volume":"153","author":"AC Karaplis","year":"2012","unstructured":"Karaplis AC, Bai X, Falet JP, Macica CM (2012) Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice. Endocrinology 153:5906\u20135917. https:\/\/doi.org\/10.1210\/en.2012-1551","journal-title":"Endocrinology"},{"key":"5997_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00774-011-0340-2","volume":"30","author":"TO Carpenter","year":"2012","unstructured":"Carpenter TO (2012) The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 30:1\u20139. https:\/\/doi.org\/10.1007\/s00774-011-0340-2","journal-title":"J Bone Miner Metab"},{"key":"5997_CR57","doi-asserted-by":"publisher","first-page":"120","DOI":"10.4248\/BR201302002","volume":"1","author":"X Huang","year":"2013","unstructured":"Huang X, Jiang Y, Xia W (2013) FGF23 and phosphate wasting disorders. Bone Res 1:120\u2013132. https:\/\/doi.org\/10.4248\/BR201302002","journal-title":"Bone Res"},{"key":"5997_CR58","doi-asserted-by":"publisher","first-page":"17","DOI":"10.17458\/per.vol17.2019.gi.fgf23anddisordersphosphate","volume":"17","author":"A Gohil","year":"2019","unstructured":"Gohil A, Imel EA (2019) FGF23 and associated disorders of phosphate wasting. Pediatr Endocrinol Rev 17:17\u201334. https:\/\/doi.org\/10.17458\/per.vol17.2019.gi.fgf23anddisordersphosphate","journal-title":"Pediatr Endocrinol Rev"},{"key":"5997_CR59","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/qjmed\/hcq039","volume":"103","author":"G Liamis","year":"2010","unstructured":"Liamis G, Milionis HJ, Elisaf M (2010) Medication-induced hypophosphatemia: a review. Q J Med 103:449\u2013459. https:\/\/doi.org\/10.1093\/qjmed\/hcq039","journal-title":"Q J Med"},{"key":"5997_CR60","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jbspin.2019.01.012","volume":"86","author":"A Lambert","year":"2019","unstructured":"Lambert A, Zhukouskaya V, Rothenbuhler A, Linglart A (2019) X-linked hypophosphatemia: management and treatment prospects. Joint Bone Spine 86:731\u2013738. https:\/\/doi.org\/10.1016\/j.jbspin.2019.01.012","journal-title":"Joint Bone Spine"},{"key":"5997_CR61","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jval.2018.01.013","volume":"21","author":"C Theodore-Oklota","year":"2018","unstructured":"Theodore-Oklota C, Bonner N, Spencer H, Arbuckle R, Chen C, Skrinar A (2018) Qualitative research to explore the patient experience of X-linked hypophosphatemia and evaluate the suitability of the BPI-SF and WOMAC\u00ae as clinical trial end points. Value Health 21:973\u2013983. https:\/\/doi.org\/10.1016\/j.jval.2018.01.013","journal-title":"Value Health"},{"key":"5997_CR62","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13052-019-0654-6","volume":"45","author":"F Emma","year":"2019","unstructured":"Emma F, Cappa M, Antoniazzi F, Bianchi ML, Chiodini I, Eller Vainicher C, di Iorgi N, Maghnie M, Cassio A, Balsamo A, Baronio F, de Sanctis L, Tessaris D, Baroncelli GI, Mora S, Brandi ML, Weber G, D\u2019Ausilio A, Lanati EP (2019) X-linked hypophosphatemic rickets: an Italian experts\u2019 opinion survey. Ital J Pediatr 45:67\u201331. https:\/\/doi.org\/10.1186\/s13052-019-0654-6","journal-title":"Ital J Pediatr"},{"key":"5997_CR63","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.3390\/ijerph15102212","volume":"15","author":"M Mazzucato","year":"2018","unstructured":"Mazzucato M, Vison\u00e0 Dalla Pozza L, Minichiello C, Manea S, Barbieri S, Toto E, Vianello A, Facchin P (2018) The epidemiology of transition into adulthood of rare diseases patients: results from a population-based registry. Int J Environ Res Public Health 15:2212. https:\/\/doi.org\/10.3390\/ijerph15102212","journal-title":"Int J Environ Res Public Health"},{"key":"5997_CR64","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3233\/TRD-190042","volume":"4","author":"M De Castro","year":"2019","unstructured":"De Castro M, Turner C, Kirmse B (2019) Practical recommendations for the transition to adulthood for the adolescent with a genetic diagnosis. Special emphasis on inborn errors of metabolism. Translational Sci Rare Dis 4:159\u2013168. https:\/\/doi.org\/10.3233\/TRD-190042","journal-title":"Translational Sci Rare Dis"},{"key":"5997_CR65","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1017\/cts.2018.338","volume":"2","author":"S Lanzkron","year":"2018","unstructured":"Lanzkron S, Sawicki GS, Hassell KL, Konstan MW, Liem RI, McColley SA (2018) Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: current practices and research priorities. J Clin Trans Sci 2:334\u2013342. https:\/\/doi.org\/10.1017\/cts.2018.338","journal-title":"J Clin Trans Sci"},{"key":"5997_CR66","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00223-017-0363-3","volume":"102","author":"VV Shanbhogue","year":"2018","unstructured":"Shanbhogue VV, Hansen S, Jorgensen NR, Beck-Nielsen SS (2018) Impact of conventional medical therapy on bone mineral density and bone turnover in adult patients with X-linked hypophosphatemia: A 6-year prospective cohort study. Calcif Tissue Int 102:321\u2013332. https:\/\/doi.org\/10.1007\/s00223-017-0363-3","journal-title":"Calcif Tissue Int"},{"key":"5997_CR67","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1210\/jcem.75.3.1517380","volume":"75","author":"W Sullivan","year":"1992","unstructured":"Sullivan W, Carpenter T, Glorieux F, Travers R, Insogna K (1992) A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 75:879\u2013885. https:\/\/doi.org\/10.1210\/jcem.75.3.1517380","journal-title":"J Clin Endocrinol Metab"},{"key":"5997_CR68","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, Kamenick\u00fd P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO, on behalf of the AXLES 1 Investigators (2018) A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of Burosumab, an anti-FGF23 antibody, in adults with X-linked Hypophosphatemia: week 24 primary analysis. J Bone Miner Res 33:1383\u20131393. https:\/\/doi.org\/10.1002\/jbmr.3475","journal-title":"J Bone Miner Res"},{"key":"5997_CR69","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/jbmr.3843","volume":"34","author":"KL Insogna","year":"2019","unstructured":"Insogna KL, Rauch F, Kamenicky P, Ito N, Kubota T, Nakamura A, Zhang L et al (2019) Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial. J Bone Miner Res 34:2183\u20132191. https:\/\/doi.org\/10.1002\/jbmr.3843","journal-title":"J Bone Miner Res"},{"key":"5997_CR70","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","volume":"105","author":"AA Portale","year":"2019","unstructured":"Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong H, Cohen-Solal M et al (2019) Continued beneficial effects of burosumab in adults with x-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int 105:271\u2013284. https:\/\/doi.org\/10.1007\/s00223-019-00568-3","journal-title":"Calcif Tissue Int"},{"key":"5997_CR71","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bone.2019.06.025","volume":"127","author":"S DeLacey","year":"2019","unstructured":"DeLacey S, Liu Z, Broyles A, El-Azab SA, Guandique CF, James BC, Imel EA (2019) Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients. Bone 127:386\u2013392. https:\/\/doi.org\/10.1016\/j.bone.2019.06.025","journal-title":"Bone"},{"key":"5997_CR72","first-page":"367","volume":"10","author":"J Lee","year":"2013","unstructured":"Lee J, Imel EA (2013) The changing face of hypophosphatemic disorders in the FGF-23 era. Pediatr Endocrinol Rev 10:367\u2013379","journal-title":"Pediatr Endocrinol Rev"},{"key":"5997_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007470.pub3","volume":"10","author":"G Bjelakovic","year":"2014","unstructured":"Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, Bjelakovic M, Gluud C, Cochrane Metabolic and Endocrine Disorders Group (2014) Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 10:CD007470. https:\/\/doi.org\/10.1002\/14651858.CD007470.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"5997_CR74","unstructured":"Crysvita, Summary of product characteristics. Last updated version, February 2020."},{"key":"5997_CR75","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40272-020-00381-8","volume":"22","author":"V Saraff","year":"2020","unstructured":"Saraff V, Nadar R, Hogler W (2020) New Developments in the Treatment of X-Linked Hypophosphataemia: Implications for Clinical Management. Pediatr Drugs 22:113\u2013121. https:\/\/doi.org\/10.1007\/s40272-020-00381-8","journal-title":"Pediatr Drugs"},{"key":"5997_CR76","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s00774-009-0079-1","volume":"27","author":"D Tiosano","year":"2009","unstructured":"Tiosano D, Hochberg Z (2009) Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab 27:392\u2013401. https:\/\/doi.org\/10.1007\/s00774-009-0079-1","journal-title":"J Bone Miner Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-05997-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-021-05997-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-05997-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T04:02:18Z","timestamp":1634097738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-021-05997-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":76,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5997"],"URL":"https:\/\/doi.org\/10.1007\/s00198-021-05997-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]},"assertion":[{"value":"18 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sandro Giannini, Maria Luisa Bianchi, Domenico Rendina, Maria Luisa Brandi declare that they have no conflict of interest. Pierfrancesco Massoletti and Debora Lazzerini are employees of Kyowa Kirin Italia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}